These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10510917)

  • 1. T-cell adoptive immunotherapy of metastatic renal cell carcinoma.
    Plautz GE; Bukowski RM; Novick AC; Klein EA; Kursh ED; Olencki TE; Yetman RJ; Pienkny A; Sandstrom K; Shu S
    Urology; 1999 Oct; 54(4):617-23; discussion 623-4. PubMed ID: 10510917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic T cell adoptive immunotherapy of malignant gliomas.
    Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S
    J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.
    To WC; Wood BG; Krauss JC; Strome M; Esclamado RM; Lavertu P; Dasko D; Kim JA; Plautz GE; Leff BE; Smith V; Sandstrom-Wakeling K; Shu S
    Arch Otolaryngol Head Neck Surg; 2000 Oct; 126(10):1225-31. PubMed ID: 11031409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
    Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
    Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
    Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
    Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
    Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
    J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study.
    Chan B; Lee W; Hu CX; Ng P; Li KW; Lo G; Ho G; Yeung DW; Woo D
    Cytotherapy; 2003; 5(1):46-54. PubMed ID: 12745587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.